Clinical effect of quadruple scheme combined with bismuth in the treatment of patients with helicobacter pylori / 中国基层医药

ABSTRACT

Objective To discuss the eradication effect and application value of quad solution containing bismuth agent in the treatment of helicobacter pylori.Methods 210 patients with helicobacter pylori infection were selected.The patients were randomly divided into three groups A,B,C,respectively,and the three group were given three different bismuth agent quadruple therapy.Group A received furazolidone, tetracycline and rabeprazole joint colloidal bismuth pectin capsules;Group B received amoxicillin and levofloxacin, rabeprazole joint colloidal bismuth pectin capsules;Group C received furazolidone, amoxicillin and rabeprazole joint colloidal bismuth pectin capsules. The treatment effect was recorded.Results There were 2,4,3 cases in A,B,C groups lost to follow-up,including 12 cases in group A positive review,positive review of 11 cases of group B,group C positive review of 13 cases,the therapeutic effect among three groups had no statistically significant difference (P>0.05).The total cost,eradication rate and C/E of group A were 198.38 yuan,82.35%,240.90,which of group B were 479.92 yuan,83.33%, 575.93,which of group C were 280.98 yuan,80.60%,348.61.C/E of group A had the most economic advantage. Conclusion Tetracycline or amoxicillin combined furazolidone, levofloxacin combined amoxicillin quad solution containing bismuth agent can be used as an effective method to the eradication of helicobacter pylori,but the tetracy-cline,furazolidone quadruple scheme through more continue to advantage,more suitable for popularization and applica-tion in clinic.